Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| 17-alpha-Estradiol | Testosterone Enanthate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | — | Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement. |
| Timing | — | Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate. |
| Cycle Duration | — | Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation. |
| Evidence Level | Preclinical | strong_human |
Non-feminizing estrogen that extends lifespan in male mice via metabolic improvements. Reduces hepatic mTOR signaling, improves glucose homeostasis, and reduces inflammation without estrogenic effects on reproductive tissues.
Testosterone enanthate is a long-acting esterified testosterone prodrug with a heptanoic acid ester at the 17-beta hydroxyl group, extending its half-life to approximately 4.5-5 days. Upon hydrolysis by tissue esterases, free testosterone activates nuclear androgen receptors, upregulating anabolic gene transcription including myostatin suppression and IGF-1 induction. It also modulates the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback on GnRH and LH secretion.
Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement.
Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate.
Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →